Pharmaceutical Technology1h
Conduit and Sarborg link to optimise AI drug development
Conduit Pharmaceuticals has signed an agreement with Sarborg to leverage advanced AI and cybernetics for the optimisation of processes related to key drug development. These include the repurposing ...
Pharmaceutical Technology2h
A novel, toothy approach to innovating randomization in clinical trials
A successful clinical trial requires an effective randomization strategy formulated by innovative thinking to meet unique demands. In a recent webinar, Solventum revealed how the eClinical platform ...
Pharmaceutical Technology4h
AIM ImmunoTech gains Netherlands patent for post-Covid fatigue therapy
AIM ImmunoTech has secured a patent from the Netherlands Patent Office for Ampligen, targeting the treatment of post-Covid fatigue.
Pharmaceutical Technology6h
Risk adjusted net present value: What is the current valuation of Eli Lilly and Co’s Olomorasib?
Olomorasib is a small molecule commercialized by Eli Lilly and Co, with a leading Phase III program in Non-Small Cell Lung Cancer.
Pharmaceutical Technology6h
Risk adjusted net present value: What is the current valuation of Pfizer’s Ponsegromab?
Ponsegromab is a monoclonal antibody commercialized by Pfizer, with a leading Phase II program in Cancer Anorexia-Cachexia Syndrome.
Pharmaceutical Technology9h
Risk adjusted net present value: What is the current valuation of Enanta Pharmaceuticals’s Zelicapavir?
Zelicapavir is a small molecule commercialized by Enanta Pharmaceuticals, with a leading Phase II program in Respiratory Syncytial Virus (RSV) Infections.
Pharmaceutical Technology9h
Risk adjusted net present value: What is the current valuation of Argenx’s Empasiprubart?
Empasiprubart is a monoclonal antibody commercialized by Argenx, with a leading Phase II program in Multifocal Motor Neuropathy.
Pharmaceutical Technology9h
Risk adjusted net present value: What is the current valuation of Eli Lilly and Co’s Lepodisiran sodium?
Lepodisiran sodium is an antisense rnai oligonucleotide commercialized by Eli Lilly and Co, with a leading Phase III program in Atherosclerosis.
Pharmaceutical Technology9h
Risk adjusted net present value: What is the current valuation of Oncolytics Biotech’s Reolysin?
Reolysin is an oncolytic virus commercialized by Oncolytics Biotech, with a leading Phase II program in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer).
Pharmaceutical Technology12h
Flu vaccine strategy on the line as new US leaders anticipated to take charge
RFK Jr’s appointment as HHS head is likely to shake up flu vaccine regulation, say experts. Credit: The Washington Post via Getty Images As countries in the Northern hemisphere deal with the flu ...
Pharmaceutical Technology12h
Roche wins Vabysmo prefilled syringe EU approval to intensify Eylea challenge
Roche’s blockbuster Vabysmo is vying for ophthalmological dominance against Regeneron’s Eylea. Image credit: Shutterstock / Marlon Trottmann. The European Medicines Agency (EMA) has approved Roche’s ...